Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naive Adults Aged 18 to 45 Years.

Next Previous
Trial Profile

Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naive Adults Aged 18 to 45 Years.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CYD TDV (Primary) ; Dengue vaccine; Japanese encephalitis vaccine
  • Indications Dengue
  • Focus Adverse reactions
  • Sponsors Sanofi Pasteur

Most Recent Events

  • 12 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 12 Mar 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
  • 12 Mar 2010 Actual patient number (154) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top